ACRS compared with LLY: revenue, margins and what each company keeps, and the suppliers and customers both name

ACRSAclaris Therapeutics, Inc.

Mkt capRevenueRevenue

LLYELI Lilly & Co

Mkt capRevenueRevenue

Compare

ACRSAclaris Therapeutics, Inc.

LLYELI Lilly & Co

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ACRS

0 of 4at or beyond implied

Reportimpliedrealized× implied

Nov 5 '26±30.0%▼−1.90%×0.06

Q3 FY26±33.1%0.00%×0.00

Q2 FY26±18.4%▼−4.25%×0.23

May 7 '26±11.5%▲+1.67%×0.15

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

= impliedACRS realized, solidLLY realized, hatchedOne scale, both sides: full bar = 34%× = |realized| ÷ impliedSource: market data

Q1 FY26

±5.3%

▲+9.80%

×1.85

Feb 4 '26±6.1%▲+10.33%×1.69

ACRSAclaris Therapeutics, Inc.

3.62· pre 3.53· delayed

Mkt cap$572.6MRevenue$1MQ3 FY26Revenue$8MFY25

LLYELI Lilly & Co

1,371.32· pre 1,363.77· delayed

Pre-marketNov 5 '26delayed

Mkt cap$1.2TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

Compare

Pre-marketNov 5 '26delayed

ACRSAclaris Therapeutics, Inc.

LLYELI Lilly & Co

3.62pre 3.53delayed

Price

1,371.32pre 1,363.77delayed

$572.6M

Mkt cap

$1.2T

Q3 FY26$1M

Revenue

$24.4BQ3 FY26

FY25$8M

Revenue

$65.2BFY25

ACRS3.62vsLLY1,371.32Pre-marketNov 5 '26delayed